Sun Pharma initiates phase II clinical trial on potential COVID-19 drug, AQCH

Sun Pharmaceutical Industries has begun with the phase II clinical trial of a phytopharmaceutical drug with the potential to treat COVID-19 patients, AQCH. It has shown anti-SARS-CoV-2 effects in in-vitro studies conducted in collaboration with the International Centre for Genetic Engineering and Biotechnology (ICGEB), Italy.

During a regulatory filing on Friday, Sun Pharma said “The clinical trial will be conducted across 12 centres in India in 210 patients. The treatment duration for patients will be 10 days. The results of the clinical trial are expected by October 2020.”

AQCH has been found safe at the recommended dose for Phase II as a human safety study of the drug has been already completed.

Managing Director of Sun Pharmaceutical Industries, Mr Dilip Sanghvi said: “These results combined with information on the mechanism of action through in-vitro and small animal studies give us the confidence to evaluate this potential treatment option for COVID-19 patients.”

In April this year, the company got the approval from the Drugs Controller General of India (DCGI) for conducting phase II clinical trial. It is the first phytopharmaceutical drug by DCHI for clinical trial as a potential treatment for novel Coronavirus.

Subscribe to our newsletter
Subscribe to our newsletter
Sign up here to get the latest news delivered directly to your inbox.
You can unsubscribe at any time